Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113998 | 0.78 | SORD (0.48) | KMT2ASMN1; SMN2ALDH1A1HRH4TSHR | |
| SCHEMBL3655755 | 0.75 | CETP (0.49) | KMT2AALDH1A1HRH4DRD2HTR6 | |
| SCHEMBL5049466 | 0.75 | CXCR4 (0.42) | KMT2ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL8980571 | 0.75 | KCNH2 (0.52) | — | |
| SCHEMBL12485821 | 0.74 | KMT2A (0.47) | KMT2ACRHBPCRHR2LMNAALDH1A1 | |
| SCHEMBL10830394 | 0.74 | CRHBP (0.50) | KMT2ASMN1; SMN2CRHBPCRHR2ALDH1A1 | |
| SCHEMBL27760246 | 0.74 | NOS3 (0.51) | KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL23781494 | 0.71 | CASP1 (0.44) | KMT2AHRH4DRD2HTR6 | |
| SCHEMBL23781493 | 0.71 | CASP1 (0.44) | KMT2AHRH4DRD2HTR6 | |
| SCHEMBL12485485 | 0.71 | MAPT (0.55) | KMT2ASMN1; SMN2LMNAMTORMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022534-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20090325954-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-12-31 | — | — | US | disclosed |
| US-20090270390-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA (SE) | 2009-10-29 | — | — | US | disclosed |
| US-20090233926-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA (SE) | 2009-09-17 | — | — | US | disclosed |
| EP-2069330-A1 | 2 -BENZIMIDAZOLYL- 6 -MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2009-06-17 | — | — | EP | disclosed |
| EP-2064203-A1 | 2-BENZIMIDAZ0LYL-6-M0RPH0LIN0-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2009-06-03 | — | — | EP | disclosed |
| EP-2061784-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2009-05-27 | — | — | EP | disclosed |
| EP-2057147-A1 | PYRIMIDINE DERIVATIVES | Astra Zeneca AB (SE) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008032064-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032072-A1 | 2-BENZIMIDAZ0LYL-6-M0RPH0LIN0-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032036-A1 | 6-BENZIMIDAZ0LYL-2-M0RPH0LIN0-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032028-A1 | 2 -BENZIMIDAZOLYL- 6 -MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032091-A1 | 4-BENZIMIDAZ0LYL-6-M0RPH0LIN0-2-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032027-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032086-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032041-A1 | PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST PI3K ENZYMES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032060-A1 | 4-BENZIMIDAZ0LYL-6-M0RPH0LIN0-2-PIPERAZINYLPYRIMIDINE DERIVATIVES AS P13K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032077-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032089-A1 | 4-BENZIMIDAZ0LYL-2-M0RPH0LIN0-6-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032033-A1 | 4-BENZIMIDAZOLYL-2-MORPHOLINO-6-PIPERAZINYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325954-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | PIK3CA, MTOR, PIK3CD | KMT2A 2315/4885SMN1; SMN2 1404/4885CRHBP 4620/4885 |
| US-20090233926-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | PIK3CA, MTOR, PIK3CD | KMT2A 1736/4885SMN1; SMN2 1546/4885CRHBP 4337/4885 |
| US-20100022534-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | MTOR, PIK3CA, PIK3CD | KMT2A 2529/4885SMN1; SMN2 1674/4885CRHBP 4831/4885 |
| US-20090270390-A1 | PYRIMIDINE DERIVATIVES | TYMP, DPYD, TYMS | KMT2A 3141/4885SMN1; SMN2 2744/4885CRHBP 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.